Pharmacokinetics of sarafloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications

被引:15
作者
Ding, HZ
Zeng, ZL
Fung, KF
Chen, ZL
Qiao, GL
机构
[1] S China Agr Univ, Dept Vet Med, Lab Vet Pharmacol, Guangzhou 510642, Peoples R China
[2] N Carolina State Univ, Coll Vet Med, Dept Anat Physiol Sci & Radiol, Raleigh, NC 27606 USA
关键词
D O I
10.1046/j.1365-2885.2001.00348.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetics of sarafloxacin, a fluoroquinolone antibiotic, was determined in pigs and broilers after intravenous (i.v.), intramuscular (i.m.), or oral (p.o.) administration at a single dose of 5 (pigs) or 10 mg/kg broilers). Plasma concentration profiles were analysed by a noncompartmental pharmacokinetic method. Following i.v., i.m. and p.o. doses, the elimination half-lives (t(1/2 beta)) were 3.37 +/- 0.46, 4.66 +/- 1.34, 7.20 +/- 1.92 (pigs) and 2.53 +/- 0.82, 6.81 +/- 2.04, 3.89 +/- 1.19 h (broilers), respectively. After i.m. and p.o. doses, bioavailabilities (F) were 81.8 +/- 9.8 and 42.6 +/- 8.2% (pigs) and 72.1 +/- 8.1 and 59.6 +/- 13.8% (broilers), respectively. Steady-state distribution volumes (V-d(ss)) of 1.92 +/- 0.27 and 3.40 +/- 1.26 L/kg and total body clearances (Cl-B) of 0.51 +/- 0.03 and 1.20 +/- 0.20 L/kg/h were determined in pigs and broilers, respectively. Areas under the curve (AUC), mean residence times (MRT), and mean absorption times (MAT) were also determined. Sarafloxacin was demonstrated to be more rapidly absorbed, more extensively distributed, and more quickly eliminated in broilers than in pigs. Based on the single-dose pharmacokinetic parameters determined, multiple dosage regimens were recommended as: a dosage of 10 mg/kg given intramuscularly every 12 h in pigs, or administered orally every 8 h in broilers, can maintain effective plasma concentrations with bacteria infections, in which MIC90 are <0.25 <mu>g/mL.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 24 条
[1]  
Aliabadi F. Shojaee, 1997, Journal of Veterinary Pharmacology and Therapeutics, V20, P14
[2]  
ANADON A, 1994, P 6 C EUR ASS VET PH, P230
[3]   Pharmacokinetics of ciprofloxacin following intravenous and oral administration in broiler chickens [J].
Atta, AH ;
Sharif, L .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1997, 20 (04) :326-329
[4]   ACTIVITY OF DIFLOXACIN (A-56619) AND A-56620 AGAINST CLINICAL ANAEROBIC-BACTERIA INVITRO [J].
BANSAL, MB ;
THADEPALLI, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (04) :619-621
[5]   Fluoroquinolones in animal health [J].
Brown, SA .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1996, 19 (01) :1-14
[6]  
Chen Z., 1994, P 6 C EUR ASS VET PH, P209
[7]   INVITRO ACTIVITIES OF A-56619 (DIFLOXACIN) AND A-56620, 2 ARYL-FLUOROQUINOLONES [J].
DIGRANES, A ;
DIBB, WL .
CHEMOTHERAPY, 1988, 34 (04) :298-307
[8]   INVITRO ACTIVITIES OF THE QUINOLONE ANTIMICROBIAL AGENTS A-56619 AND A-56620 [J].
ELIOPOULOS, GM ;
MOELLERING, AE ;
REISZNER, E ;
MOELLERING, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (04) :514-520
[9]  
Fang BingHu, 1999, Chinese Journal of Veterinary Science, V19, P588
[10]   INVIVO EVALUATION OF A-56619 (DIFLOXACIN) AND A-56620 - NEW ARYL-FLUOROQUINOLONES [J].
FERNANDES, PB ;
CHU, DTW ;
BOWER, RR ;
JARVIS, KP ;
RAMER, NR ;
SHIPKOWITZ, N .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (02) :201-208